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and daily activities (placebo, –0.0001 [–0.002, 0.002], P= 0.9; LDX relative to placebo, 
0.0006 [–0.002, 0.003], P= 0.6) or after adjusting for BE days/week, functionality, and 
impairment in work and daily activities (placebo, –0.0008 [–0.003, 0.002], P= 0.5; LDX 
relative to placebo, 0.0002 [–0.002, 0.003], P= 0.9). ConClusions: The positive effect 
of LDX on HRQoL/patient utlility is indirect and mediated in part by LDX effects on 
BE frequency and disability/functioning.
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objeCtives: To evaluate the effect of lisdexamfetamine dimesylate (LDX) and 
changes in binge eating (BE) days/week and BE episodes/week on disability in 
patients with protocol-defined moderate to severe binge eating disorder (BED) over 
12 weeks. Methods: In two identically designed, 12-week, double-blind, placebo 
(PBO)-controlled trials, adults meeting DSM-IV-TR BED criteria were randomized 
(study 1, N= 383; study 2, N= 390) to PBO or LDX (50 or 70 mg). LDX was statistically 
superior to PBO in reducing the number of BE days/week (the primary endpoint) 
and showed numerical improvements in BE episodes/week (a secondary endpoint). 
The trials assessed disability with Sheehan Disability Scale (SDS) as an explora-
tory endpoint. Observations corresponding to visits from baseline to week 12 were 
analyzed; data were pooled across studies. The current post hoc analyses were 
performed using mixed-effect logistic regression models to determine the relation-
ship between: (1) LDX therapy and disability, and (2) BE days/week and disability, 
and BE episodes/week and disability. P-values are unadjusted and presented for 
descriptive purposes only. Results: LDX therapy showed a numeric improvement 
on disability as measured by SDS. The odds ratio (OR)/week for disability (> 0 score) 
measured by SDS total score for LDX relative to placebo was 0.70 (P≤ 0.001). Higher 
BE frequency counteracted the improvement in disability which was significant 
in the lowest tertile of BE frequency (tertile 3). ORs/week for disability (> 0 score) 
measured by SDS total score in BE days/week tertiles 1, 2 and 3 (relative to tertile 1) 
were 0.66, 1.37 and 1.72, and in BE episodes/week 0.66, 1.44 and 1.69, respectively (all 
P≤ 0.001). ConClusions: Findings of this longitudinal analysis indicate that LDX 
therapy has a positive effect on disability, as measured by SDS, of BED patients. The 
analysis also showed that reduction in both BE days/week and BE episodes/week is 
associated with improvement in disability over 12 weeks.
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objeCtives: Treatment continuation of four long acting, injectable, antipsychotic 
drugs: paliperidone palmitate, risperidone microspheres, olanzapine pamoate and 
haloperidol decanoate, was evaluated in the Dutch outpatient setting using panel 
data from public pharmacies. Restart rates, maintenance dose distribution, age dis-
tribution and frequency of co-prescriptions were also investigated. Methods: The 
IMS LifelinkTM Treatment Dynamics database was used, applying appropriate selec-
tion criteria. Four patient cohorts that started paliperidone palmitate, risperidone 
microspheres, olanzapine pamoate or haloperidol decanoate treatment, between 
1 April 2011 and 31 March 2012, and 1 October 2012 and 31 September 2013 were 
analyzed. All cohorts included at least 13 months of follow up. Treatment continua-
tion was investigated. Results: After 180 days, in both study periods, a significantly 
higher percentage of patients continued treatment with paliperidone palmitate. 
After six months, respectively 59% and 55% of patients continued paliperidone pal-
mitate. For risperidone microspheres this was 42% and 40%, for olanzapine pamoate 
25% and 43%, and for haloperidol decanoate 42% and 47%. In both study periods, sig-
nificantly higher percentages of patients restarted index treatment within 3 months 
when using paliperidone palmitate (42% and 40%) or olanzapine pamoate (44% and 
42%) compared to risperidone microspheres (35% and 33%) or haloperidol decanoate 
(26% and 28%). For all therapies, dosing was comparable between treatment initia-
tion and discontinuation. Medication used to treat extrapyramidal symptoms was 
on average more frequently used with haloperidol decanoate (24% and 18%) than 
with paliperidone palmitate (4% and 5%) risperidone microspheres (11% and 3%), or 
olanzapine pamoate (0 and 6%). ConClusions: Results of the database research 
indicate that a higher percentage of patients treated with paliperidone palmitate 
continued therapy and restarted therapy than patients receiving the other three 
long-acting antipsychotics. Co-medication against extrapyramidal symptoms was 
more frequently used with haloperidol decanoate. FINANCIAL SUPPORT: This work 
was funded by Janssen.
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objeCtives: Dementia is known as a major public health problem affecting both 
patients and caregivers, and placing a high financial strain upon society. In com-
munity-dwelling patients, it is important to support informal caregivers in order 
to help them sustain their demanding role. Previous reviews about effectiveness 
of such supporting strategies often included a small number of studies, focused 
objeCtives: Major Depressive Disorder (MDD) may significantly affect cognitive 
domains of attention, concentration and memory. While the burden of cogni-
tive dysfunction in Schizophrenia is well established, the investigation of cogni-
tive impairment in Bipolar Disorder (BD) and MDD has attracted the interest of 
research only more recently. Therefore, it is of great interest to understand cli-
nician’s perception about cognitive dysfunction in MDD and to raise awareness 
about this issue. Methods: Between December 2014 and January 2015, 128 Italian 
psychiatrists were recruited to participate to an on-line survey whose aim was 
to understand psychiatrists’ perception about cognitive symptoms in MDD. The 
questionnaire comprised three sections: the first investigating psychiatrists’ socio-
demographic and professional profile, the second assessing cognitive symptoms rel-
evance without mentioning they represented the study focus and the third explicitly 
investigating cognitive symptoms. Results: Cognitive symptoms were considered 
a relevant dimension of MDD and they appeared amongst the most frequently 
cited residual symptoms compromising patients’ work and influencing relapse risk. 
About 70% of psychiatrists declared that cognitive symptoms significantly influ-
ence the antidepressant choice. However, in the previous questionnaire section 
where focus on cognitive symptoms was not revealed yet, cognitive symptoms 
appeared less frequently considered for antidepressant choice. ConClusions: 
Study results revealed a clear understanding of cognitive symptoms relevance in 
MDD. Nevertheless, the discrepancy between psychiatrists’ perception and their 
therapeutical choices underlines the presence of an unmet need that should be 
addressed increasing the awareness about the positive effects on cognitive symp-
toms of existing drugs, which could allow a more symptom-oriented therapeutical 
intervention.
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objeCtives: Ketamine has demonstrated rapid and robust antidepressant effects 
in patients with treatment resistant depression (TRD) in investigational clinical 
trials. The objective of this study was to compare the efficacy of ketamine with 
other pharmacological and somatic treatments in adult TRD patients. Methods: 
A systematic literature review was performed in September 2014, using a predefined 
search strategy including MEDLINE, EMBASE and the Cochrane Library. TRD was 
defined as ≥ 2 antidepressant treatment failures. Thirty-one randomized controlled 
trials (RCTs) were included: 19 RCTs investigating 13 pharmacological interven-
tions and 12 RCTs investigating electroconvulsive therapy (ECT) or repetitive tran-
scranial magnetic stimulation (rTMS). Key outcomes were: disease severity change 
from baseline at 2 weeks measured on the Montgomery–Åsberg Depression Rating 
Scale (MADRS) and response rate at 2 weeks (i.e. reduction of ≥ 50% in MADRS total 
score). Placebo and sham arms were pooled into one reference group.The evidence 
base was synthesised by means of a Bayesian network meta-analysis. Results: 
Ketamine seemed more efficacious in reducing depressive symptoms at 2 weeks 
than aripiprazole augmentation (mean difference in MADRS reduction -11.0; 95% 
Credible Interval [CrI] -17.8 to -4.1), venlafaxine monotherapy(-12.7; [-23.2 to -2.2]), 
olanzapine/fluoxetine combination (-12.5; [-24.9 to -0.2]), fluoxetine monotherapy 
(-12.5; [-24.4 to -0.6]), quetiapine augmentation (-11.6; [-20 to -3.1]), nortriptyline 
monotherapy (-13; [-25.7 to -0.3]), lamotrigine augmentation (-13.2; [-24.2 to -2.2]), 
ECT (-9.4; [-18.4 to -0.5]) and rTMS (-9.8; [-16.2 to -3.5]). Also, ketamine showed the 
highest probability of being the best treatment (57%). The % responders at 2 weeks 
was 5-fold higher for ketamine than for aripiprazole (odds ratio (OR) 5.2; 95% CrI 
[1.4-27.5]) and rTMS (4.8; [1.1-27.5]), and 14-fold higher compared to placebo/sham 
treatment (13.7; [3.8-69.1]). ConClusions: Based on the evidence synthesis of 
available RCTs investigating the efficacy of TRD treatments at 2 weeks, ketamine 
demonstrated superior efficacy compared with other pharmacological and somatic 
interventions.
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objeCtives: To evaluate the effects of lisdexamfetamine dimesylate (LDX) on 
changes in health-related quality of life (HRQoL) in individuals with protocol-
defined moderate to severe binge eating disorder (BED). Methods: In 2 identically 
designed 12-week, double-blind, placebo-controlled trials, adults with protocol-
defined moderate to severe binge eating (BE) who met DSM-IV-TR BED criteria were 
randomized (study 1, N= 383; study 2, N= 390) to placebo or LDX (50 or 70 mg). HRQoL 
was assessed at baseline and treatment weeks 4, 6, 8, 10, and 12/early termination 
using the EuroQoL 5-Dimension 5-Level Questionnaire (EQ-5D-5L; a prespecified 
secondary endpoint). For this post hoc analysis, participant EQ-5D-5L profiles were 
converted to utility index scores (range: –0.109 [worst state] to 1 [best state]) and 
pooled across studies. Unadjusted and adjusted random effect tobit regressions 
were conducted to examine the longitudinal relationship between LDX treatment 
and HRQoL. Results: Mean ± SD EQ-5D-5L index scores in the pooled treatment 
groups were 0.877±0.105 for placebo (n= 358 observations) and 0.882±0.118 for LDX 
(n= 364 observations) at baseline and 0.909±0.115 for placebo (n= 296 observations) 
and 0.933±0.102 for LDX (n= 302 observations) at week 12. Mean (95% CI) improve-
ment/week in EQ-5D-5L index scores without adjustment was statistically sig-
nificant for placebo (0.0059 [0.005, 0.007]; P< 0.001) and for LDX relative to placebo 
(0.0032 [0.001, 0.005]; P= 0.001). Treatment effects on HRQoL were no longer signifi-
cant after adjusting for BE episodes/week, functionality, and impairment in work 
